MarketCap
Facebook
X
TelegramQuarterly report 2025-Q4
added 01-08-2026
Tilray Total Liabilities 2011-2026 | TLRY
Annual Total Liabilities Tilray
| 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 977 M | 1.01 B | 1.56 B | 660 M | 708 M | 140 M | 42.1 M | 1.27 M | 947 K | 30 K | 11 K | 11 K | - |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 1.56 B | 11 K | 425 M |
Quarterly Total Liabilities Tilray
| 2025-Q4 | 2025-Q3 | 2025-Q2 | 2025-Q1 | 2024-Q4 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 552 M | 562 M | 585 M | - | 701 M | 778 M | 778 M | 870 M | 778 M | 1 B | 977 M | 969 M | 991 M | 1.03 B | 1.01 B | 1.01 B | 1.29 B | 1.6 B | 1.56 B | 1.56 B | 572 M | 701 M | 724 M | 725 M | 611 M | 611 M | 611 M | 611 M | 459 M | 459 M | 459 M | 459 M | 58.8 M | 58.8 M | 58.8 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 1.6 B | 58.8 M | 758 M |
Total Liabilities of other stocks in the Drug manufacturers industry
| Issuer | Total Liabilities | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
Aurora Cannabis
ACB
|
244 M | $ 3.55 | 2.76 % | $ 86.3 M |  Canada |
 |
Alimera Sciences
ALIM
|
107 M | - | - | $ 142 M |  USA |
 |
Adamis Pharmaceuticals Corporation
ADMP
|
11.6 M | - | 0.86 % | $ 117 M | USA |
 |
Aerie Pharmaceuticals
AERI
|
449 M | - | - | $ 754 M | USA |
 |
AcelRx Pharmaceuticals
ACRX
|
10.2 M | - | 7.5 % | $ 6.35 M | USA |
 |
Canopy Growth Corporation
CGC
|
430 M | $ 1.07 | 4.92 % | $ 115 M | Canada |
 |
Agile Therapeutics
AGRX
|
26.6 M | - | 10.11 % | $ 58.2 M | USA |
 |
Cronos Group
CRON
|
218 M | $ 2.54 | 0.07 % | $ 1.32 B | Canada |
 |
Assertio Holdings
ASRT
|
173 M | $ 11.64 | -1.1 % | $ 74.5 M | USA |
 |
DURECT Corporation
DRRX
|
63.2 M | - | - | $ 50.1 M | USA |
 |
Avadel Pharmaceuticals plc
AVDL
|
90.4 M | - | - | $ 2.06 B |  France |
 |
Eagle Pharmaceuticals
EGRX
|
173 M | - | -39.89 % | $ 27.7 M | USA |
 |
Evolus
EOLS
|
249 M | $ 4.94 | -1.98 % | $ 318 M | USA |
 |
Evoke Pharma
EVOK
|
9.65 M | - | - | $ 36.6 M | USA |
 |
Calliditas Therapeutics AB (publ)
CALT
|
250 M | - | -0.1 % | $ 2.03 B |  Schweden |
 |
HEXO Corp.
HEXO
|
367 M | - | 2.45 % | $ 38.1 M | Canada |
 |
Catalent
CTLT
|
6.15 B | - | - | $ 11.5 B | USA |
 |
Cumberland Pharmaceuticals
CPIX
|
53 M | $ 3.22 | 5.23 % | $ 45.3 M | USA |
 |
Jupiter Wellness
JUPW
|
9.51 M | - | - | $ 33.6 M | USA |
 |
OrganiGram Holdings
OGI
|
102 M | $ 1.45 | 2.11 % | $ 402 M | Canada |
 |
Athenex
ATNX
|
228 M | - | -23.39 % | $ 1.76 M | USA |
 |
Endo International plc
ENDP
|
10.3 B | - | - | $ 28.9 M |  Irlanda |
 |
Organogenesis Holdings
ORGO
|
113 M | $ 2.61 | 1.16 % | $ 344 M | USA |
 |
Harrow Health
HROW
|
347 M | $ 34.42 | -1.4 % | $ 1.27 B | USA |
 |
Pacira BioSciences
PCRX
|
775 M | $ 22.28 | -1.81 % | $ 1.03 B | USA |
 |
Emergent BioSolutions
EBS
|
1.17 B | $ 8.27 | -0.72 % | $ 423 M | USA |
 |
Sundial Growers
SNDL
|
216 M | $ 1.46 | 1.26 % | $ 3.37 M | Canada |
 |
China Pharma Holdings
CPHI
|
7.14 M | $ 0.64 | 3.22 % | $ 11.2 M |  China |
 |
Veru
VERU
|
28.1 M | $ 2.44 | 2.74 % | $ 329 M | USA |
 |
Viatris
VTRS
|
28.9 B | $ 13.79 | 2.04 % | $ 16.6 B | USA |
 |
ProPhase Labs
PRPH
|
24 M | - | - | $ 5.07 M | USA |
 |
TherapeuticsMD
TXMD
|
14 M | $ 2.18 | 0.46 % | $ 22.8 M | USA |
 |
Lannett Company
LCI
|
735 M | - | 1.15 % | $ 7.11 M | USA |
 |
Radius Health
RDUS
|
434 M | - | - | $ 1.42 B | USA |
 |
Perrigo Company plc
PRGO
|
5.6 B | $ 10.18 | 4.68 % | $ 1.41 B | USA |
 |
Neoleukin Therapeutics
NLTX
|
36.5 M | - | - | $ 193 M | Canada |
 |
Sonoma Pharmaceuticals
SNOA
|
9.28 M | $ 2.44 | 1.25 % | $ 3.03 M | USA |
 |
Relmada Therapeutics
RLMD
|
12.2 M | $ 6.32 | 2.27 % | $ 190 M | USA |
 |
Rockwell Medical
RMTI
|
30.9 M | $ 1.01 | 5.73 % | $ 23.6 M | USA |
 |
PetIQ
PETQ
|
478 M | - | 1.64 % | $ 400 M | USA |
 |
OptiNose
OPTN
|
194 M | - | - | $ 1.08 B | USA |
 |
PLx Pharma
PLXP
|
25 M | - | -27.8 % | $ 2.56 M | USA |
 |
SCYNEXIS
SCYX
|
9.65 M | $ 0.93 | 3.16 % | $ 46.4 M | USA |
 |
Recro Pharma
REPH
|
94.8 M | - | -4.76 % | $ 65.3 M | USA |
 |
Solid Biosciences
SLDB
|
51.4 M | $ 7.65 | 2.27 % | $ 312 M | USA |
 |
Tricida
TCDA
|
168 M | - | - | $ 3.25 M | USA |
 |
cbdMD
YCBD
|
8.62 M | $ 0.74 | 1.97 % | $ 3.19 M | USA |
 |
Zynerba Pharmaceuticals
ZYNE
|
9.29 M | - | - | $ 55.5 M | USA |
 |
Zomedica Corp.
ZOM
|
11.6 M | - | -0.21 % | $ 98 M | USA |